Immunohistochemical expression of uPA, PAl-l, cathepsin D and apoptotic cells in ductal carcinoma m situ of the breast

Breast Cancer

Volumn 9, Issue 2, 2002, Pages 118-126

  Zhao, Haiying ^a,b   Morimoto, Tadaoki ^b   Sasa, Mitsunori ^c   Tanaka, Takashi ^c   Izumi, Keisuke ^d  

^a Medical University   (China)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

^d UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Breast cancer; Ductal carcinoma in situ (DCIS); Immunohistochemical methods; Invasive marker; Proliferative marker

Indexed keywords

CATHEPSIN D; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR MARKER; UROKINASE;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST TUMOR; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; CULTURE TECHNIQUE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; NEEDLE BIOPSY; PAGET NIPPLE DISEASE; PATHOLOGY; PROBABILITY; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BIOPSY, NEEDLE; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CATHEPSIN D; CHI-SQUARE DISTRIBUTION; CULTURE TECHNIQUES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROBABILITY; PROGNOSIS; RECEPTOR, ERBB-2; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 0036360538     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02967576     Document Type: Article

References (28)

1. Look MP and Foekens JA: Clinical relevance of the urokinase plasminogen activator system in breast cancer. APMIS 107:150-159, 1999. (Pubitemid 29133535)
2. Rochefort H and Liaudet-Coopman E: Cathepsin D in cancer metastasis: A protease and a ligand. APMIS 107:86-95, 1999. (Pubitemid 29133527)
3. Kim SJ, Shiba E, Kobayashi T, Yayoi E, Furukawa J, Takatsuka Y, Shin E, Koyama H, Inaji H and Takai S: Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-l, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Clin Cancer Res 4:177-182, 1998. (Pubitemid 28062893)
4. Foekens JA, Look MP, Boil-de Vries J, Meijer-van Gelder ME, van Putten WLJ and Klijn JGM: Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Brit J Cancer 79:300-307, 1999. (Pubitemid 29002300)
5. Knoop A, Andreasen PA, Andersen JA, Hansen S, Laenkholm A-V, Simonsen ACW, Andersen J, Overgaard J and Rose C: Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Brit J Cancer 77:932-940, 1998. (Pubitemid 28101782)
6. Jahkola T, Tolvonen T, von Smitten K, Virtanen I, Wasenius V-M and Blomqvist C: Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors. Brit J Cancer 80:167-174, 1999. (Pubitemid 29210103)
7. Ioachim Elli, Kamina Sebasti, Kontostolis Manolis and Agnantis Niki J: Immunohistochemical expression of cathepsin D in correlation with extracellular matrix component, steroid receptor status and proliferative indices in breast cancer. Virchows Arch 431:311-316, 1997.
8. Meijer-van Gelder ME, Look MP, Bolt-de Vries J, Peters HA, Klijn JGM and Fiekens J A: Breast-conserving therapy: proteases as risk factors in relation to survival after local relapse. J Clin Oncol 17:1449-1457, 1999. (Pubitemid 29220851)
9. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD and Miles DW: Overexpression of cerbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Brit J Cancer 79:1220-1226, 1999. (Pubitemid 29087902)
10. Wright C, Angus B, Nicholson S, Sainsbury J. RC, Cairns J, Gullick WJ, Kelly P, Harris AL and Wilson HCH: Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 49:2087-2090, 1989. (Pubitemid 19106519)
11. Watanabe E, Toyoda M, Okuda J, Tenjo T, Tanaka K, Yamamoto T, Kawasaki H, Sugiyama T, Kawarada Y and Tanigawa N: Detection of apoptotic cells in human colorectal cancer by two different in situ methods: antibody against single-stranded DNA and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling (TUNEL) methods. Jpn J Cancer Res 90:188-193, 1999. (Pubitemid 29112319)
12. Frankfurt OS, Robb JA, Sugarbaker EV and Villa L: Monoclonal antibody to single-stranded DNA is a specific and sensitive cellular marker of apoptosis. Exp Cell Res 226:387-397, 1996. (Pubitemid 26260564)
13. Schnitt SJ, Silen W, Sadowsky NL, Connolly JL and Harris JR: Ductal carcinoma in situ (intraductal carcinoma) of the breast. N Engl J Med 318:898-903, 1988. (Pubitemid 18090275)
14. Lagios MD, Margolin FR, Westdahl PR and Rose MR: Mammographically detected duct carcinoma in situ. Frequency of local recurrence following lumpectomy and prognostic effect of nuclear grade on local recurrence. Cancer 63:618-624, 1989. (Pubitemid 19050259)
15. Holland R, Hendriks JHCL, Verbeek ALM, Mravunac M and Schuurmans Stekhoven JH: Extent, distribution and mammographic/histological correlations of breast ductal carcinoma in situ. Lancet 335:519-522, 1990. (Pubitemid 20073065)
16. Fisher ER, Dignam J, Tan-Chiu E, Costantino J, Fisher B, Paik S and Wolmark N: Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP): Eight-year update of protocol B-17. Cancer 86:429-438, 1999. (Pubitemid 29347405)
17. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG, K~rdinal CG, Kavanah MT, Fehrenbacher L, Oishi RH: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial Lancet 353:1993-2000, 1999. (Pubitemid 29271743)
18. Silverstein MJ, Poller DN, Waisman J R, Colburn WJ, Barth A, Gierson ED, Lewinsky B, Gamagami P and Slamon DJ: Prognostic classification of breast ductal carcinoma-in-situ. Lancet 345:1154-1157, 1995.
19. Silverstein MJ, Lagios MD, Craig PH, Waisman JR, Lewinsky BS, Colburn WJ and Poller DN: A prognostic index for ductal carcinoma in situ of the breast. Cancer 77:2267-2274, 1996. (Pubitemid 26162419)
20. Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver MJ and Zafrani B: Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 11:167-180, 1994. (Pubitemid 24308077)
21. Isola J, Weitz S, Visakorpi T, Holli K, Shea R, Khabbaz N, and Kallioniemi OP: Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. J Clin Oncol 11:36-43, 1993. (Pubitemid 23059972)
22. Barnes DM, Lammie GA, Millis RR, Gullick WL, Allen DS and Altman DG: An immunohistochemical evaluation of c-erbB2 expression in human breast carcinoma. Br J Cancer 58:448-452, 1998.
23. Merchant WJ, Millis RR, Smith P, Chaudary MA and Barnes DM: Expression of C-erbB2 and p53 protein is similar in breast cancer from British and Japanese women. IntJ Cancer 84:278-283, 1999. (Pubitemid 29256755)
24. Vakkala M, Lahteenmaki K, Raunio H, Paakko P and Soini Y: Apoptosis during breast carcinoma progression. Clin Cancer Res 5:319-324, 1999. (Pubitemid 29085184)
25. Frankfurt OS, Robb JA, Sugarbaker EV and Villa L: Apoptosis in breast carcinomas detected with monoclonal antibody to single-stranded DNA: relation to bcl-2 expression, hormone receptors, and lymph node metastases. Clin Cancer Res 3:465-471, 1997. (Pubitemid 27158072)
26. Harbeck N, Dettmar P, Thomssen C, Berger U, Ulm K, Kates R, Hofler H, Janicke F, Graeff H and Schmitt M: Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up. Br J Cancer 80:419-426, 1999. (Pubitemid 29213195)
27. Eppenberger U, Kueng W, Schlawppi JM, Roesel JL, Benz C, Mueller H, Matter A, Zuber M, Luescher K, Litschgi M, Schmitt M, Foekens JA and Eppenberger-Castofi S: Markers of tumor angiogenesis and proteolysis independently define high and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 16:3129-3136, 1998. (Pubitemid 28417436)
28. Dublin E, Hanby A, Patel NK Liebman R, Barnes D: Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology. Am J Pathol 157:1219-1227, 2000.